What is the market's earnings forecast for EDAP TMS next quarter?

What is EDAP TMS's gross profit margin?

What guidance did EDAP TMS's management provide for the next earnings period?

What factors drove the changes in EDAP TMS's revenue and profit?

What were the key takeaways from EDAP TMS’s earnings call?

What were the key takeaways from EDAP TMS's earnings call?

What is the revenue and EPS growth rate for EDAP TMS year over year?

What is EDAP TMS's latest dividend and current dividend yield?

- **Revenue Milestones**: Q3 2025 HIFU revenue up 49% YoY to €6.7M; U.S. procedures grow 15% YoY. 8 Focal One placements (167% YoY growth).
- **Clinical Validation**: HIFU non-inferior to radiation therapy in 10-year study; endometriosis Phase III RCT shows sustained symptom improvement.
- **Financial Strength**: Gross margin 43% (vs. 39.4% YoY); €11M EIB funding supports growth. 2025 guidance reaffirmed at €58-62M.
- **Strategic Wins**: 21/35 SUO programs adopt Focal One; WCET 2025 Industry Award for innovation. BPH U.S. trial underway.

**【CEO Summary Section】**
- **Record Revenue Growth**: Q3 2025 total revenue of €13.9M, with HIFU revenue up 49% YoY to €6.7M. U.S. Focal One procedures grew 15% YoY, returning to double-digit growth.
- **Clinical Adoption Expansion**: 8 Focal One placements (6 capital sales, 2 leases), up 167% YoY. Now integrated into 21/35 SUO-approved fellowship programs, training future urologists.
- **Reimbursement Progress**: Medicare Advantage coverage driving hospital economics; CMS rules reinforce HIFU's Medicare pathway.
- **Clinical Evidence Strength**: Peer-reviewed study shows HIFU non-inferior to radiation therapy for 10-year oncological outcomes. Endometriosis Phase III RCT shows sustained symptom improvement, with 85% sham patients opting for HIFU post-unblinding.
- **New Indications**: BPH U.S. clinical study IRB approved at Mount Sinai; European endometriosis limited launch underway. Focal One i awarded 2025 WCET Industry Award for innovation.

**【CFO Financial Commentary】**
- **Gross Margin Expansion**: 43% Q3 2025 vs. 39.4% YoY, driven by high-margin HIFU business. 9M 2025 gross margin 42.5% vs. 39.9% YoY.
- **Operational Efficiency**: Operating loss €4.9M (down €1M YoY). Cash €10.6M after EIB €11M tranche receipt. Tariff impact forecasted at €900K annually.
- **Balance Sheet Health**: Inventory optimized to €13.8M. New ultrasound scanner supplier to reduce costs in 2026.
- **Guidance Reaffirmed**: 2025 core HIFU revenue growth 26-34%, non-core ESWL/distribution down 25-30%.

**【Q&A Highlights】**
- **EIB Proceeds Usage**: Funds allocated to product development, clinical trials (e.g., BPH, endometriosis), and commercial growth. No short-term dilution to equity.
- **Procedure Coverage Mix**: Medicare, Medicare Advantage, and commercial payers. Medicare Advantage expansion driving growth.
- **Q4 Outlook**: Maintain 2025 guidance of €58-62M revenue. No quarterly guidance, but confident in achieving annual targets.

EDAP TMS S.A. (EDAP) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: Q2 HIFU revenue up 89% YoY to $9.7M, driven by 12 system placements (9 capital sales). CMS reimbursement increases validate growth.
- **Clinical Validation**: Landmark HIFI/FARP studies boost confidence; 80% of sham trial patients opted for Focal One post-unblinding.
- **Innovation Lead**: Focal One i launched with remote proctoring; first U.S. system performed procedures Q2. Endometriosis CE mark achieved.
- **Strategic Funding**: €36M EIB facility to accelerate HIFU adoption and new indications (BPH, histotripsy).
- **Market Expansion**: 4 Focal One placements at Cleveland Clinic sites; multi-system sales to major hospital networks signal accelerating adoption.

**【CEO Summary Section】**
- **Q2 2025 Performance**: Global HIFU revenue reached $9.7 million, up 89% YoY, driven by 12 Focal One system placements (9 capital sales, 3 operating leases). U.S. procedures grew 4.8% YoY.
- **Clinical Validation**: Landmark HIFI and FARP studies support Focal One's efficacy, with 80% of sham arm patients in endometriosis trials opting for Focal One post-unblinding.
- **Product Innovation**: Focal One i launched with advanced imaging and robotic features, enabling remote proctoring. First U.S. system performed procedures Q2.
- **Reimbursement Progress**: CMS proposed 5.6% increase in 2026 hospital payment ($9,765) and higher RVUs (26.43) vs. competitors (IRE: 19.76, waterjet: 16.14). New CPT code for BPH ablation established.
- **Strategic Expansion**: 4 Focal One placements at Cleveland Clinic sites globally. Endometriosis CE mark achieved, with limited European launch underway.
- **New Financing**: Letter of intent for €36M (≈$42M) EIB facility to accelerate HIFU adoption and R&D.

**【CFO Financial Commentary】**
- **Revenue**: Total Q2 2025 revenue €16M (+1.6% YoY). HIFU revenue €8.5M (+76.8% YoY), offset by 31.2% decline in non-core ESWL/distribution.
- **Profitability**: Gross margin 42.5% (vs. 37.5% YoY), driven by HIFU focus. Operating loss €5.8M (vs. €6.1M YoY). Net loss €5.6M (-9% YoY).
- **Cash Flow**: €16.3M cash at end Q2, down from €22.8M due to strategic investments. €15.5M inventory reduction via just-in-time management.
- **Tariff Impact**: 15% U.S.-France tariff forecasted, monitoring go-forward effects.

**【Q&A Highlights】**
- **Payer Challenges**: Medicare Advantage delays resolved in most regions; HIFU procedure approvals improving. CMS reimbursement increases validate clinical value.
- **Growth Momentum**: Q2 marked inflection point with record placements. 3+ hospital networks acquiring second Focal One systems (e.g., NewYork-Presbyterian, Baptist Health).
- **BPH Pipeline**: Phase I/II BPH study recruiting in France; U.S. clinical trial planned for 2026. CPT Category III code enables investigational BPH procedures.
- **Endometriosis Update**: CE-marked Focal One i launched in Europe. Study shows noninvasive HIFU matches surgery efficacy with faster recovery.
- **EIB Financing**: €36M facility expected to close soon, funding HIFU expansion and new indications (e.g., histotripsy).
- **Procedure Growth**: Q2 U.S. procedures +4.8% YoY; pipeline strengthened with expanded sales team and clinical data dissemination.

EDAP TMS S.A. (EDAP) Q2 2025 Earnings Conference Call Transcript

- **Q1 Record Placement**: 9 Focal One systems sold, including 6 cash sales to major U.S. health systems
- **Clinical Validation**: FARP RCT shows non-inferiority to radical prostatectomy (6.5% failure rate)
- **New Product Launch**: Focal One i with AI, remote surgery capabilities
- **Growth Targets**: 16-25% HIFU revenue growth, despite 10% U.S. tariff impact
- **Payer Challenge**: 54% of patients on Medicare Advantage face longer approvals, but 80%+ appeals approved

**【CEO Strategic Overview】**
- Q1 2025: 9 Focal One systems placed (record for any Q1), including 6 cash sales and 3 leases in U.S. and international markets.
- Key milestones: CE Mark approval for endometriosis, launch of Focal One i robotic system, and first remote transatlantic procedure.
- Clinical validation: FARP RCT shows 6.5% treatment failure vs 8.5% for radical prostatectomy, matching HIFI study results.
- Strategic focus: Expand Focal One adoption in large healthcare networks (e.g., Baylor, Methodist, Kaiser Permanente).

**【CFO Financial Highlights】**
- HIFU revenue: €6.2M (6.8% YoY growth)
- Total revenue: €13.6M (-9.1% YoY) due to non-core business decline
- Gross margin: 42% (stable vs 42.8% YoY)
- Operating loss: €6M (€4.8M YoY) driven by R&D and commercial investments
- Cash: €22.8M (€29.8M Q4 2024)
- Tariff impact: 10% for Q2 on U.S. imports from France

**【Q&A Key Takeaways】**
- Payer challenges: 54% of patients on Medicare Advantage face longer pre-authorization times, but 80%+ appeals approved
- Growth drivers: Focal One i features (AI, remote collaboration), expanding clinical evidence (FARP/HIFI), and controlled endometriosis launch in Europe
- 2025 guidance: HIFU revenue +16-25%, non-core -20-25% YoY
- Risk: U.S. tariffs could add 10%+ cost on Focal One systems

EDAP TMS S.A. (EDAP) Q1 2025 Earnings Call Transcript

- **CE Mark Milestone**: Focal One now approved for endometriosis in 26 European countries, opening new market opportunities.
- **Q4 Revenue Beat**: HIFU revenue up 15% YoY, driven by 7 U.S. system sales and 31% YoY procedure growth.
- **HIFI Study Impact**: Landmark clinical trial results position Focal One as first-line prostate cancer treatment, accelerating adoption.
- **2025 Growth Guidance**: HIFU revenue expected to grow 16-25% YoY, fueled by pipeline strength and CMS reimbursement uplift.
- **Strategic Shift**: Divesting low-margin businesses to focus on high-growth HIFU, with 2025 non-core revenue decline of 20-25%.
- **Clinical Expansion**: Active trials in endometriosis, BPH, and pancreatic cancer expand addressable patient population.


**【CEO Key Updates】**
- **CE Mark for Endometriosis**: Focal One received CE Mark for treating deep infiltrating endometriosis, enabling controlled market entry in 26 European countries.
- **Q4 Financial Highlights**: HIFU revenue grew 15% YoY to $9.3M, with 11 system sales (7 in the U.S., including 2 lease conversions). Global HIFU revenue rose 15.3% YoY in 2024.
- **Procedure Growth**: U.S. Focal One procedures increased 31% YoY in Q4, driven by adoption of the landmark HIFI study, which demonstrated superior functional outcomes vs. radical prostatectomy.
- **Strategic Shifts**: Phasing out ESWL and legacy distribution businesses (20-25% YoY decline), reallocating resources to high-growth HIFU. 2025 HIFU revenue guidance: 16-25% YoY growth.

**【CFO Financial Summary】**
- **Full Year 2024**: Total revenue €64.1M (+6.1% YoY), with HIFU revenue €23.8M (+15.7% YoY). Gross margin improved to 44.8% (Q4 2024 vs. 43.7% Q4 2023).
- **Q4 2024**: Operating loss €3.7M (-5.1% YoY). Net loss €1.9M (-62% YoY). Cash balance €29.8M, up €4.3M QoQ.
- **Tariff Impact**: Minimal risk to Focal One supply chain, with potential medical device exemptions.

**【Q&A Highlights】**
- **Pipeline Strength**: CEO cites strongest pipeline ever, with 50%+ U.S. SUO fellowship programs using Focal One.
- **Reimbursement Impact**: 5.4% CMS rate increase (Jan 2025) enhances hospital ROI, supporting 2025 procedure growth.
- **Endometriosis Strategy**: Focused on clinical collaboration with experts to refine Phase I launch post-CE Mark.
- **BPH Development**: New CPT code (July 2025) enables claims for BPH procedures, with Phase I/II trials ongoing in France.
- **Pancreatic Trial**: Early-stage PULS trial in France targeting locally advanced pancreatic tumors.

**【2025 Outlook】**
- **HIFU Growth Drivers**: System sales, procedure volume expansion, and service revenue from growing installed base.
- **Non-Core Businesses**: ESWL to transition to service-only model, with margin improvement despite revenue decline.
- **Operating Expenses**: Mid-single-digit YoY increase, balanced against HIFU growth investments.


Actual														-0.0352	0.0367	0.0353	-0.0119	-0.0347	0.0455	0.0111	0.0524	0	-0.1498	-0.2168	-0.1418	-0.1163	-0.1545	-0.1295	-0.1714		-0.0518	-0.2056	-0.1767	-0.1525
Forecast														-0.0176	0.0897	-0.0107	-0.0119	-0.0083	0.0072	-0.028	-0.0343	-0.054	-0.0048	-0.0312	-0.0513	-0.1132	-0.0453	-0.1151	-0.1366		-0.1046	-0.1632	-0.2139	-0.2541	-0.1367
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	-59.09%	+429.91%	0.00%	-318.07%	+531.94%	+139.64%	+252.77%	+100.00%	-3020.83%	-594.87%	-176.41%	-2.74%	-241.06%	-12.51%	-25.48%	0.00%	+50.48%	-25.98%	+17.39%	+39.98%	0.00%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	11.08M	18.80M	12.10M	12.27M	10.93M	15.88M	14.38M	14.83M	12.00M	16.82M	16.03M	15.57M	12.41M	21.65M	16.09M	16.91M	--	21.03M	14.67M	18.90M	16.29M	--
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	9.18M	19.94M	12.42M	12.30M	12.16M	15.04M	12.96M	13.73M	11.80M	16.83M	14.95M	16.93M	15.91M	20.12M	16.04M	17.08M	--	20.11M	16.44M	16.30M	15.13M	21.58M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+20.64%	-5.71%	-2.56%	-0.26%	-10.11%	+5.60%	+10.99%	+8.04%	+1.67%	-0.03%	+7.24%	-8.03%	-22.00%	+7.57%	+0.27%	-1.00%	0.00%	+4.58%	-10.76%	+15.95%	+7.66%	0.00%

EDAP

EDAP fundamentals

EDAP Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

EDAP

EDAP fundamentals

EDAP Q4 2025 Earnings Preview

Earnings Call

EDAP Earnings Call Summary for Q4/2025Today8:30 AM on Mar 25, 2026

EDAP Earnings Call Summary for Q3/20258:30 AM on Nov 6, 2025

EDAP Earnings Call Summary for Q2/20258:30 AM on Aug 28, 2025

EDAP Earnings Call Summary for Q1/20258:30 AM on May 15, 2025

EDAP Earnings Call Summary for Q4/20248:30 AM on Mar 27, 2025

You can ask Aime